Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2RL1 | P55085 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 9/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | CNR1 | P21554 | 1/20 | 0.49 |
| ▸ | SLC2A1 | P11166 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.45 |
| ▸ | AKT1 | P31749 | 1/20 | 0.44 |
| ▸ | AKT2 | P31751 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15071097 | 0.86 | HPGD (0.55) | F2RL1HPGDMAPK1CNR1NPC1 | |
| SCHEMBL15071100 | 0.83 | F2RL1 (0.77) | F2RL1HPGDMAPK1CNR1NPC1 | |
| SCHEMBL15071143 | 0.81 | F2RL1 (0.74) | F2RL1HPGDMAPK1CNR1SLC2A1 | |
| SCHEMBL21500651 | 0.80 | AKT1 (0.56) | HPGDNPC1RAB9ATSHRALDH1A1 | |
| SCHEMBL2127536 | 0.78 | AKT1 (0.58) | HPGDNPC1RAB9ATSHRALDH1A1 | |
| SCHEMBL15050221 | 0.76 | F2RL1 (0.53) | F2RL1HPGDNPC1RAB9ATSHR | |
| SCHEMBL5337926 | 0.75 | CNR1 (0.58) | F2RL1HPGDCNR1SLC2A1KMT2A | |
| SCHEMBL5322233 | 0.75 | CNR1 (0.58) | F2RL1HPGDCNR1SLC2A1KMT2A | |
| SCHEMBL15071099 | 0.75 | F2RL1 (0.52) | F2RL1HPGDNPC1RAB9ATSHR | |
| SCHEMBL31560 | 0.75 | F2RL1 (0.63) | F2RL1HPGDMAPK1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2617721-A2 | NOVEL HETEROCYCLIC COMPOUND, AND COMPOSITION FOR TREATING INFLAMMATORY DISEASES USING SAME | Neopharm Co., Ltd. (KR) | 2013-07-24 | — | — | EP | disclosed |
| US-20130165652-A1 | NOVEL HETEROCYCLIC COMPOUND, AND COMPOSITION FOR TREATING INFLAMMATORY DISEASES USING SAME | NEOPHARM CO.,LTD. (KR) | 2013-06-27 | — | — | US | disclosed |
| US-20130165652-A1 | NOVEL HETEROCYCLIC COMPOUND, AND COMPOSITION FOR TREATING INFLAMMATORY DISEASES USING SAME | NEOPHARM CO.,LTD. (KR) | 2013-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165652-A1 | NOVEL HETEROCYCLIC COMPOUND, AND COMPOSITION FOR TREATING INFLAMMATORY DISEASES USING SAME | F2RL1, F2R, FPR2 | F2RL1 1/4885HPGD 80/4885MAPK1 1566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.